☆ 4.4 Article

Clearance as an Early Indicator of Efficacy for Therapeutic Monoclonal Antibodies: Circumventing Dose Selection Challenges in Oncology

CLINICAL PHARMACOKINETICS (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

Lihua E. Budde et al.

Summary: This study evaluated the safety, tolerability, and efficacy of mosunetuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs). The results showed that mosunetuzumab has a manageable safety profile and induces durable complete responses in some patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

David Cella et al.

Summary: In the CheckMate 9ER trial, nivolumab plus cabozantinib demonstrated improved patient-reported outcomes compared to sunitinib in the treatment of advanced renal cell carcinoma. The combination treatment resulted in maintained or improved PRO scores and significantly delayed time to deterioration of PRO scores compared to sunitinib.

LANCET ONCOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Tebentafusp: First Approval

Sohita Dhillon

Summary: Tebentafusp is a targeted therapy for uveal melanoma and malignant melanoma that binds to specific receptors and T cells, resulting in the direct lysis of tumor cells. It has received approval for the treatment of uveal melanoma in the USA and is under regulatory review in other countries.

DRUGS (2022)

Add to Collection

Article Oncology

Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis

Jie Cai et al.

Summary: Pancreatic cancer has poor prognosis and high mortality rates, leading to increased research on its epidemiology. Advances in the field include trends, risk factors, prediction models, screening methods, and prognosis. Risk factors are related to individual characteristics, lifestyle, environment, and disease status. Prediction models have been developed for populations with new-onset diabetes or family history of pancreatic cancer, but require further validation. Despite progress in screening, more studies are needed to identify high-risk populations and develop effective screening methods.

CANCER LETTERS (2021)

Add to Collection

Editorial Material Medicine, General & Internal

The Drug-Dosing Conundrum in Oncology - When Less Is More

Mirat Shah et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Pharmacology & Pharmacy

Which factors matter the most? Revisiting and dissecting antibody therapeutic doses

Yu Tang et al.

Summary: Factors such as antibody clearance and target affinity can influence antibodies' effective doses for specific indications. A dimensionless metric called TEAR was used to normalize therapeutic doses for direct and quantitative comparisons. The study highlights the importance of antibodies' modes of action in determining therapeutic doses and dose selections.

DRUG DISCOVERY TODAY (2021)

Add to Collection

Review Oncology

Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers

Angelo Paci et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

Bispecific antibodies: a mechanistic review of the pipeline

Aran F. Labrijn et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

Add to Collection

Review Oncology

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

Fabio Conforti et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment

Pamela L. Clemens et al.

CLINICAL PHARMACOKINETICS (2017)

Add to Collection

Article Hematology

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

Tineke Casneuf et al.

BLOOD ADVANCES (2017)

Add to Collection

Article Oncology

Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer

Yan Feng et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Pharmacology & Pharmacy

Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma

X. Wang et al.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)

Add to Collection

Article Pharmacology & Pharmacy

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors

M. Ahamadi et al.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)

Add to Collection

Article Pharmacology & Pharmacy

Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors

G. Bajaj et al.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)

Add to Collection

Review Pharmacology & Pharmacy

Translational Medicine Guide transforms drug development processes: the recent Merck experience

Hugues Dolgos et al.

DRUG DISCOVERY TODAY (2016)

Add to Collection

Article Oncology

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

Shruti Agrawal et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)

Add to Collection

Article Oncology

Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies

Diego Tosi et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Review Pharmacology & Pharmacy

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

Nathanael L. Dirks et al.

CLINICAL PHARMACOKINETICS (2010)

Add to Collection

Review Oncology

Dose Escalation Methods in Phase I Cancer Clinical Trials

Christophe Le Tourneau et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)

Add to Collection

Article Oncology

Phase I clinical trial design in cancer drug development

EA Eisenhauer et al.

JOURNAL OF CLINICAL ONCOLOGY (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.